Overview

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with multiple sclerosis. The escalation part of the study will determine the maximum tolerated dose (MTD) or the Maximum Administered Dose if no MTD is found.
Phase:
Phase 1
Details
Lead Sponsor:
Vaccinex Inc.
Collaborator:
PRA Health Sciences